ADAMTS2 drives prostate cancer progression by activating FAK/PI3K/AKT signaling and suppressing ferroptosis via COL1A1
Frontiers in Oncology · 27.04.2026 · 16
DOI: 10.3389/fonc.2026.1784882 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Oncology, online erschienen am 27.04.2026. Verfasst von Jinzhuo Ning und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Renmin Hospital of Wuhan University, Wuhan, Hubei, China. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Background
ADAMTS2, a secreted metalloproteinase essential for collagen maturation, exhibits context-dependent roles in cancer but remains uncharacterized in prostate cancer (PCa). Its potential involvement in PCa progression and underlying mechanisms are unknown.
Methods
We integrated bioinformatic analysis of TCGA-PRAD data with clinical specimen validation, in vitro functional assays (proliferation, migration, invasion), co-immunoprecipitation (Co-IP), ferroptosis sensitivity testing, pharmacological inhibition, and in vivo xenograft models to investigate ADAMTS2’s expression, function, and molecular mechanisms in PCa.
Results
ADAMTS2 was significantly upregulated in PCa tissues and cell lines, correlating with aggressive clinicopathological features and poor progression-free survival. Functionally, ADAMTS2 promoted PCa cell aggressiveness in vitro and tumor growth in vivo . Mechanistically, ADAMTS2 directly interacted with and upregulated COL1A1, leading to stimulation of the FAK/PI3K/AKT pathway. This cascade, in turn, enhanced the expression of ferroptosis defense proteins (SLC7A11 and GPX4), suppressed lipid peroxidation, and conferred resistance to ferroptosis. Pharmacological inhibition of FAK reversed both the oncogenic and anti-ferroptotic effects of ADAMTS2.
Conclusions
Our investigation considers ADAMTS2 as a novel oncogenic driver in PCa that promotes tumor progression by reinforcing a tumor-permissive extracellular matrix through upregulation of COL1A1 and by stimulating the FAK/PI3K/AKT pathway to suppress ferroptosis. These findings position ADAMTS2 as a potential predictive biomarker and a valuable therapeutic target for defeating ferroptosis resistance in PCa.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Urology, Renmin Hospital of Wuhan University, Wuhan, Hubei, China.
- Department of Urology, The First Affiliated Hospital of Hainan Medical University, Haikou, Hainan, China.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Ning, J., Wang, J., Xu, L., Zhou, Z., & Li, H. (2026). ADAMTS2 drives prostate cancer progression by activating FAK/PI3K/AKT signaling and suppressing ferroptosis via COL1A1. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1784882
Vancouver
Ning J, Wang J, Xu L, Zhou Z, Li H. ADAMTS2 drives prostate cancer progression by activating FAK/PI3K/AKT signaling and suppressing ferroptosis via COL1A1. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1784882
BibTeX
@article{Ning2026,
author = {Ning, Jinzhuo and Wang, Jinrun and Xu, Lizhe and Zhou, Zhiyan and Li, Haoyong},
title = {ADAMTS2 drives prostate cancer progression by activating FAK/PI3K/AKT signaling and suppressing ferroptosis via COL1A1},
journal = {Frontiers in Oncology},
year = {2026},
volume = {16},
doi = {10.3389/fonc.2026.1784882}
}
EUVIMED